CD19 and acute lymphoblastic leukemia: In a study of children and young adults with B-ALL enriched for patients with progressive disease after CD19-directed therapy, CD22 CAR T cells induced a 73% CR rate with equal effectiveness in CD19+ and CD19− B-ALL22,31.